BBP
RVNC

Banco BTG Pactual’s Revance Therapeutics, Inc. RVNC Stock Holding History

Banco BTG Pactual’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-24,200
Closed -$447K – 208
2022
Q4 		$447K Buy
+24,200
New +$554K 0.26% 78

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Banco BTG Pactual's RVNC Position: Q1 2023 in Review

Banco BTG Pactual sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2023, closing a stake of 24,200 shares — an estimated $447K sold.

Banco BTG Pactual first reported a position in RVNC in Q4 2022 and held it in 1 quarter. The position peaked at $447K in Q4 2022. 216 funds tracked by Wall St. Rank hold RVNC as of Q1 2023.

  • Banco BTG Pactual reported no remaining Revance Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Banco BTG Pactual sold 24,200 Revance Therapeutics, Inc. shares in Q1 2023, an estimated $447K.
  • Banco BTG Pactual first reported a position in Revance Therapeutics, Inc. in Q4 2022 and held it in 1 quarter.
  • Banco BTG Pactual's Revance Therapeutics, Inc. position peaked at $447K in Q4 2022.
  • 216 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2023.

Based on Banco BTG Pactual's 13F filing for Q1 2023, filed 10 May 2023.